DSCO, Discovery Laboratories Inc.

HTDS, Hard to Treat Diseases

DrStockPick Watch List!

DrStockPick.com Watch List! for Tuesday September 15, 2009

My Picks for Tuesday September 15, 2009 are:

**************************************************************

DSCO, Discovery Laboratories Inc.

DSCO is a biotechnology company committed to the development and commercialization of novel Surfactant Replacement Therapies (SRTs™) with potential application across the respiratory disease continuum. Surfactant is produced naturally in the lungs and is essential for normal breathing throughout life.

DSCO’s product platform is based on a novel pulmonary surfactant technology intended to establish a completely new, therapeutic approach in the treatment of respiratory disease, with a targeted initial application in

THRX, Theravance, Inc.

PWRM, Power 3 Medical Products Inc, PWRM.OB

SPNG, SpongeTech Delivery Systems Inc, SPNG.OB

DrStockPick Watch List!

DrStockPick.com Watch List! for Monday September 14, 2009

My Picks for Monday September 14, 2009 are:

**************************************************************

SPNG, SpongeTech Delivery Systems Inc, SPNG.OB

SPNG is a company which designs, produces and markets innovative, cost-effective, and environmentally sensitive packaging and product delivery solutions through its exclusive patented packaging technology.

SPNG plans to apply for a NASDAQ listing. Its Board of Directors has unanimously approved a reverse split of SpongeTech®’s issued and outstanding capital stock at a 1-for-100 split ratio. The reverse stock split demonstrates its commitment to

Headquartered in Hayward, California, Aradigm Corp. engages in developing inhalation drug products that enhance the quality of life of patients with severe pulmonary disease. Founded in 1991, the company has a team of scientists, engineers, and clinical experts who have been at the forefront of development of advanced inhalation delivery products.

Aradigm Corp.’s team pioneered the AERx® iDMS pulmonary delivery of insulin used in Phase 3 clinical trials conducted by their partner Novo Nordisk. Today, with experience and expertise in inhalation delivery, Aradigm is positioning their company to develop a portfolio of their own products to treat patients with severe respiratory diseases. The company’s current pipeline includes products undergoing development by Aradigm, or in partnerships with others, for the treatment of cystic fibrosis, inhalation anthrax, and pulmonary arterial hypertension. Aradigm Corp. is also investigating the use of their technology for tobacco smoking cessation therapy.

Aradigm’s AERx pulmonary drug delivery platform demonstrated